Foghorn reports $243.8M cash runway into 2027; pipeline milestones for FHD-909, CBP/EP300 degraders

Foghorn Therapeutics Inc.

Preliminary cash, equivalents and marketable securities of $243.8M as of Dec 31, 2024; runway into 2027.
Phase 1 trial of oral SMARCA2 inhibitor FHD-909 for SMARCA4-mutated cancers advancing; NSCLC primary target.
Preclinical combination data for FHD-909 with pembrolizumab and KRAS inhibitors to be presented at AACR April 2025.
Selective ARID1B degradation achieved; program update expected in 2025. ARID1B implicated in up to 5% of solid tumors.
Selective CBP and EP300 degrader programs advancing with preclinical data showing anti-tumor activity and tolerability.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.